Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BellRock Brands Inc. (DXBRF)
Denver, CO, US
BellRock Brands Inc. is an enterprise engaged in the development, commercialization, and distribution of cannabis-based products across the United States, Canada, and international markets. The company's extensive product line encompasses a variety of cannabis-infused offerings for adult use, including edibles, confections, beverages, and concentrates. It also provides a comprehensive range of topical solutions such as transdermal patches, lotions, creams, tinctures, and cosmetic serums, in addition to vape products and capsules. Beyond cannabis, BellRock Brands also supplies branded hemp-derived products catering to both human and animal consumers. Its impressive brand roster features prominent names like Mary's Medicinals, Mary's Nutritionals, Mary's Methods, Mary's Tails, Beezle, Dixie, Synergy, Mindset, Aceso, Therabis, Défoncé, and Rebel Coast. Prior to October 2020, the entity operated under the name Dixie Brands Inc. Its corporate headquarters are situated in Denver, Colorado. Since October 10, 2022, BellRock Brands Inc. has functioned as a subsidiary of West 4th Holdings, LLC.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +400.00% | +400.00% | -50.00% | +4,900.00% | -50.00% | +400.00% | -99.91% | -99.98% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+91.6% ★ Q2'20: +2.8% (vs Q2'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+54.3% ★ Q2'20: +52.9% (vs Q2'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-196.5% Q2'20: -31.0% (vs Q2'19)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-165.9% Q2'20: -76.4% (vs Q2'19)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'20: +224.0% (vs Q2'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+115.7% Q2'20: +0.6% (vs Q2'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.15× Q2'20: -0.30× (vs Q2'19)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sat Joshi | Chief Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DXBRF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
